Results 81 to 90 of about 62,049 (255)
Revenue Protection for Organic Producers: Too Much or Too Little?
Journal of Agricultural and Resource Economics, 2012 A framework is developed to examine organic crop insurance established by the Risk Management Agency (RMA). Given that the RMA links organic and conventional crop prices, the model is calibrated to reflect both markets to illustrate the impacts that ...
Ariel Singerman +2 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
A PERFORMANCE ANALYSIS OF TAKAFUL AND CONVENTIONAL INSURANCE IN BAHRAIN
Abstract: This research paper measures the efficiency of life insurance industry in Bahrain. While the major focus of this study is to compare the performance of takaful operators in comparison to conventional insurance during the period of 2009 to 2012.
Dr. Ghassan Fateen Abu Alsoud1 +1 more
openaire +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source
SHARIA-COMPLIANT DEPOSIT INSURANCE AND DEPOSIT FLOWS: EVIDENCE FROM A DUAL BANKING MARKET
Journal of Islamic Monetary Economics and FinanceWe investigate whether the introduction of Islamic Deposit Insurance (IDI) affects deposit flow of and the pricing by Islamic banks vis-à-vis conventional banks for the case of Indonesia.
Putra Pamungkas +2 more
doaj +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Exploring new avenues: Psychedelic‐assisted therapy for young people
British Journal of Clinical Pharmacology, EarlyView.Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou +3 more
wiley +1 more source
British Educational Research Journal, EarlyView.Abstract This study examines the under‐theorized political role and identity of Chinese international students, who emerge as significant actors caught between U.S. soft power ambitions and rising geopolitical suspicion. Amid escalating U.S.‐China tensions, these students are forced to confront environments shaped by competing geopolitical discourses ...
Jing Yu
wiley +1 more source
Toward clone‐on‐a‐chip: Ethical and legal considerations for organ‐on‐a‐chip evolution
BMEMat, EarlyView.The term “clone‐on‐a‐chip (CoC)” is introduced as a conceptual warning for personalized organ‐on‐a‐chip platforms and not to suggest technological feasibility, where a CoC ethical discussion extends beyond issues arising from the requirements for informed consent, property rights, commercialization efforts, and cell sourcing to include potentially ...
Muhammed Erkan Karabekmez +6 more
wiley +1 more source